These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 24103749

  • 1. The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro.
    Li Q, Song XM, Ji YY, Jiang H, Xu LG.
    Biochem Biophys Res Commun; 2013 Nov 01; 440(4):701-6. PubMed ID: 24103749
    [Abstract] [Full Text] [Related]

  • 2. Targeting mTOR by CZ415 Inhibits Head and Neck Squamous Cell Carcinoma Cells.
    Xie J, Li Q, Ding X, Gao Y.
    Cell Physiol Biochem; 2018 Nov 01; 46(2):676-686. PubMed ID: 29621758
    [Abstract] [Full Text] [Related]

  • 3. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia.
    Willems L, Chapuis N, Puissant A, Maciel TT, Green AS, Jacque N, Vignon C, Park S, Guichard S, Herault O, Fricot A, Hermine O, Moura IC, Auberger P, Ifrah N, Dreyfus F, Bonnet D, Lacombe C, Mayeux P, Bouscary D, Tamburini J.
    Leukemia; 2012 Jun 01; 26(6):1195-202. PubMed ID: 22143671
    [Abstract] [Full Text] [Related]

  • 4. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
    Jordan NJ, Dutkowski CM, Barrow D, Mottram HJ, Hutcheson IR, Nicholson RI, Guichard SM, Gee JM.
    Breast Cancer Res; 2014 Jan 23; 16(1):R12. PubMed ID: 24457069
    [Abstract] [Full Text] [Related]

  • 5. CC-223 inhibits human head and neck squamous cell carcinoma cell growth.
    Wang JY, Jin X, Zhang X, Li XF.
    Biochem Biophys Res Commun; 2018 Feb 19; 496(4):1191-1196. PubMed ID: 29402408
    [Abstract] [Full Text] [Related]

  • 6. Pan-mammalian target of rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by down-regulating Mcl-1 protein.
    Preuss E, Hugle M, Reimann R, Schlecht M, Fulda S.
    J Biol Chem; 2013 Dec 06; 288(49):35287-96. PubMed ID: 24133218
    [Abstract] [Full Text] [Related]

  • 7. AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.
    Guichard SM, Curwen J, Bihani T, D'Cruz CM, Yates JW, Grondine M, Howard Z, Davies BR, Bigley G, Klinowska T, Pike KG, Pass M, Chresta CM, Polanska UM, McEwen R, Delpuech O, Green S, Cosulich SC.
    Mol Cancer Ther; 2015 Nov 06; 14(11):2508-18. PubMed ID: 26358751
    [Abstract] [Full Text] [Related]

  • 8. Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion.
    Kauffman EC, Lang M, Rais-Bahrami S, Gupta GN, Wei D, Yang Y, Sourbier C, Srinivasan R.
    BMC Cancer; 2019 Sep 13; 19(1):917. PubMed ID: 31519159
    [Abstract] [Full Text] [Related]

  • 9. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y, Xi Q, Chen Y, Wang J, Peng P, Xia S, Yu S.
    Anticancer Drugs; 2013 Oct 13; 24(9):889-98. PubMed ID: 23838676
    [Abstract] [Full Text] [Related]

  • 10. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
    Mohan S, Vander Broek R, Shah S, Eytan DF, Pierce ML, Carlson SG, Coupar JF, Zhang J, Cheng H, Chen Z, Van Waes C.
    Clin Cancer Res; 2015 Sep 01; 21(17):3946-56. PubMed ID: 25977343
    [Abstract] [Full Text] [Related]

  • 11. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA, Stechishin OD, Nguyen SA, Lun XQ, Cairncross JG, Weiss S.
    Clin Cancer Res; 2014 Nov 15; 20(22):5756-67. PubMed ID: 25316808
    [Abstract] [Full Text] [Related]

  • 12. Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells.
    Sini P, James D, Chresta C, Guichard S.
    Autophagy; 2010 May 15; 6(4):553-4. PubMed ID: 20364113
    [Abstract] [Full Text] [Related]

  • 13. The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent.
    Li C, Cui JF, Chen MB, Liu CY, Liu F, Zhang QD, Zou J, Lu PH.
    Cancer Biol Ther; 2015 May 15; 16(1):34-42. PubMed ID: 25692620
    [Abstract] [Full Text] [Related]

  • 14. HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.
    English DP, Roque DM, Carrara L, Lopez S, Bellone S, Cocco E, Bortolomai I, Schwartz PE, Rutherford T, Santin AD.
    Gynecol Oncol; 2013 Dec 15; 131(3):753-8. PubMed ID: 24012800
    [Abstract] [Full Text] [Related]

  • 15. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.
    Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, Vincent JP, Ellston R, Jones D, Sini P, James D, Howard Z, Dudley P, Hughes G, Smith L, Maguire S, Hummersone M, Malagu K, Menear K, Jenkins R, Jacobsen M, Smith GC, Guichard S, Pass M.
    Cancer Res; 2010 Jan 01; 70(1):288-98. PubMed ID: 20028854
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy induction and down-regulation of p62/sequestosome 1.
    Huang S, Yang ZJ, Yu C, Sinicrope FA.
    J Biol Chem; 2011 Nov 18; 286(46):40002-12. PubMed ID: 21949121
    [Abstract] [Full Text] [Related]

  • 17. The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.
    D'Amato V, Rosa R, D'Amato C, Formisano L, Marciano R, Nappi L, Raimondo L, Di Mauro C, Servetto A, Fusciello C, Veneziani BM, De Placido S, Bianco R.
    Br J Cancer; 2014 Jun 10; 110(12):2887-95. PubMed ID: 24823695
    [Abstract] [Full Text] [Related]

  • 18. CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization.
    Mortensen DS, Fultz KE, Xu S, Xu W, Packard G, Khambatta G, Gamez JC, Leisten J, Zhao J, Apuy J, Ghoreishi K, Hickman M, Narla RK, Bissonette R, Richardson S, Peng SX, Perrin-Ninkovic S, Tran T, Shi T, Yang WQ, Tong Z, Cathers BE, Moghaddam MF, Canan SS, Worland P, Sankar S, Raymon HK.
    Mol Cancer Ther; 2015 Jun 10; 14(6):1295-305. PubMed ID: 25855786
    [Abstract] [Full Text] [Related]

  • 19. Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer.
    Qian J, Chen Y, Meng T, Ma L, Meng L, Wang X, Yu T, Zask A, Shen J, Yu K.
    Oncotarget; 2016 Oct 11; 7(41):67071-67086. PubMed ID: 27563814
    [Abstract] [Full Text] [Related]

  • 20. Autophagy induction contributes to GDC-0349 resistance in head and neck squamous cell carcinoma (HNSCC) cells.
    Zhou Y, Peng Y, Tang H, He X, Wang Z, Hu D, Zhou X.
    Biochem Biophys Res Commun; 2016 Aug 19; 477(2):174-80. PubMed ID: 27291151
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.